Cargando…
Computational simulations of tumor growth and treatment response: Benefits of high-frequency, low-dose drug regimens and concurrent vascular normalization
Implementation of effective cancer treatment strategies requires consideration of how the spatiotemporal heterogeneities within the tumor microenvironment (TME) influence tumor progression and treatment response. Here, we developed a multi-scale three-dimensional mathematical model of the TME to sim...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249820/ https://www.ncbi.nlm.nih.gov/pubmed/37289729 http://dx.doi.org/10.1371/journal.pcbi.1011131 |
_version_ | 1785055624901427200 |
---|---|
author | Nikmaneshi, Mohammad R. Jain, Rakesh K. Munn, Lance L. |
author_facet | Nikmaneshi, Mohammad R. Jain, Rakesh K. Munn, Lance L. |
author_sort | Nikmaneshi, Mohammad R. |
collection | PubMed |
description | Implementation of effective cancer treatment strategies requires consideration of how the spatiotemporal heterogeneities within the tumor microenvironment (TME) influence tumor progression and treatment response. Here, we developed a multi-scale three-dimensional mathematical model of the TME to simulate tumor growth and angiogenesis and then employed the model to evaluate an array of single and combination therapy approaches. Treatments included maximum tolerated dose or metronomic (i.e., frequent low doses) scheduling of anti-cancer drugs combined with anti-angiogenic therapy. The results show that metronomic therapy normalizes the tumor vasculature to improve drug delivery, modulates cancer metabolism, decreases interstitial fluid pressure and decreases cancer cell invasion. Further, we find that combining an anti-cancer drug with anti-angiogenic treatment enhances tumor killing and reduces drug accumulation in normal tissues. We also show that combined anti-angiogenic and anti-cancer drugs can decrease cancer invasiveness and normalize the cancer metabolic microenvironment leading to reduced hypoxia and hypoglycemia. Our model simulations suggest that vessel normalization combined with metronomic cytotoxic therapy has beneficial effects by enhancing tumor killing and limiting normal tissue toxicity. |
format | Online Article Text |
id | pubmed-10249820 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-102498202023-06-09 Computational simulations of tumor growth and treatment response: Benefits of high-frequency, low-dose drug regimens and concurrent vascular normalization Nikmaneshi, Mohammad R. Jain, Rakesh K. Munn, Lance L. PLoS Comput Biol Research Article Implementation of effective cancer treatment strategies requires consideration of how the spatiotemporal heterogeneities within the tumor microenvironment (TME) influence tumor progression and treatment response. Here, we developed a multi-scale three-dimensional mathematical model of the TME to simulate tumor growth and angiogenesis and then employed the model to evaluate an array of single and combination therapy approaches. Treatments included maximum tolerated dose or metronomic (i.e., frequent low doses) scheduling of anti-cancer drugs combined with anti-angiogenic therapy. The results show that metronomic therapy normalizes the tumor vasculature to improve drug delivery, modulates cancer metabolism, decreases interstitial fluid pressure and decreases cancer cell invasion. Further, we find that combining an anti-cancer drug with anti-angiogenic treatment enhances tumor killing and reduces drug accumulation in normal tissues. We also show that combined anti-angiogenic and anti-cancer drugs can decrease cancer invasiveness and normalize the cancer metabolic microenvironment leading to reduced hypoxia and hypoglycemia. Our model simulations suggest that vessel normalization combined with metronomic cytotoxic therapy has beneficial effects by enhancing tumor killing and limiting normal tissue toxicity. Public Library of Science 2023-06-08 /pmc/articles/PMC10249820/ /pubmed/37289729 http://dx.doi.org/10.1371/journal.pcbi.1011131 Text en © 2023 Nikmaneshi et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Nikmaneshi, Mohammad R. Jain, Rakesh K. Munn, Lance L. Computational simulations of tumor growth and treatment response: Benefits of high-frequency, low-dose drug regimens and concurrent vascular normalization |
title | Computational simulations of tumor growth and treatment response: Benefits of high-frequency, low-dose drug regimens and concurrent vascular normalization |
title_full | Computational simulations of tumor growth and treatment response: Benefits of high-frequency, low-dose drug regimens and concurrent vascular normalization |
title_fullStr | Computational simulations of tumor growth and treatment response: Benefits of high-frequency, low-dose drug regimens and concurrent vascular normalization |
title_full_unstemmed | Computational simulations of tumor growth and treatment response: Benefits of high-frequency, low-dose drug regimens and concurrent vascular normalization |
title_short | Computational simulations of tumor growth and treatment response: Benefits of high-frequency, low-dose drug regimens and concurrent vascular normalization |
title_sort | computational simulations of tumor growth and treatment response: benefits of high-frequency, low-dose drug regimens and concurrent vascular normalization |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249820/ https://www.ncbi.nlm.nih.gov/pubmed/37289729 http://dx.doi.org/10.1371/journal.pcbi.1011131 |
work_keys_str_mv | AT nikmaneshimohammadr computationalsimulationsoftumorgrowthandtreatmentresponsebenefitsofhighfrequencylowdosedrugregimensandconcurrentvascularnormalization AT jainrakeshk computationalsimulationsoftumorgrowthandtreatmentresponsebenefitsofhighfrequencylowdosedrugregimensandconcurrentvascularnormalization AT munnlancel computationalsimulationsoftumorgrowthandtreatmentresponsebenefitsofhighfrequencylowdosedrugregimensandconcurrentvascularnormalization |